Effects of metformin on hyperglycemia in an experimental model of tacrolimus- and sirolimus- induced diabetic rats
2
조회
0
다운로드
4
인용
0
참고문헌
키워드
초록
Background/Aims: Metformin (MET) is a first-line drug for type 2 diabetes mellitus (DM); its effect on new-onset diabetes after transplantation caused by immunosuppressant therapy is unclear. We compared the effects of MET on DM caused by tacrolimus (TAC) or sirolimus (SRL). Methods: DM was induced by injection of TAC (1.5 mg/kg) or SRL (0.3 mg/kg) for 2 weeks in rats, and MET (200 mg/kg) was injected for 2 more weeks. The effects of MET on DM caused by TAC or SRL were evaluated using an intraperitoneal glucose tolerance test (IPGTT) and by measuring plasma insulin concentration, islet size, and glucose-stimulated insulin secretion (GSIS). The effects of MET on the expression of adenosine monophosphate-activated protein kinase (AMPK), a pharmacological target of MET, were compared between TAC- and SRL-treated islets. Results: IPGTT showed that both TAC and SRL induced hyperglycemia and reduced plasma insulin concentration compared with vehicle. These changes were reversed by addition of MET to SRL but not to TAC. Pancreatic islet cell size was decreased by TAC but not by SRL, but addition of MET did not affect pancreatic islet cell size in either group. MET significantly increased GSIS in SRL- but not in TAC-treated rats. AMPK expression was not affected by TAC but was significantly decreased in SRL-treated islets. Addition of MET restored AMPK expression in SRL-treated islets but not in TAC-treated islets. Conclusions: MET has different effects on hyperglycemia caused by TAC and SRL. The discrepancy between these drugs is related to their different mechanisms causing DM.
Abstract
Background/Aims: Metformin (MET) is a first-line drug for type 2 diabetes mellitus (DM); its effect on new-onset diabetes after transplantation caused by immunosuppressant therapy is unclear. We compared the effects of MET on DM caused by tacrolimus (TAC) or sirolimus (SRL). Methods: DM was induced by injection of TAC (1.5 mg/kg) or SRL (0.3 mg/kg) for 2 weeks in rats, and MET (200 mg/kg) was injected for 2 more weeks. The effects of MET on DM caused by TAC or SRL were evaluated using an intraperitoneal glucose tolerance test (IPGTT) and by measuring plasma insulin concentration, islet size, and glucose-stimulated insulin secretion (GSIS). The effects of MET on the expression of adenosine monophosphate-activated protein kinase (AMPK), a pharmacological target of MET, were compared between TAC- and SRL-treated islets. Results: IPGTT showed that both TAC and SRL induced hyperglycemia and reduced plasma insulin concentration compared with vehicle. These changes were reversed by addition of MET to SRL but not to TAC. Pancreatic islet cell size was decreased by TAC but not by SRL, but addition of MET did not affect pancreatic islet cell size in either group. MET significantly increased GSIS in SRL- but not in TAC-treated rats. AMPK expression was not affected by TAC but was significantly decreased in SRL-treated islets. Addition of MET restored AMPK expression in SRL-treated islets but not in TAC-treated islets. Conclusions: MET has different effects on hyperglycemia caused by TAC and SRL. The discrepancy between these drugs is related to their different mechanisms causing DM.
참고문헌 (31)
- Hjelmesaeth J, "Hypoadiponectinemia is associated with insulin resistance and glucose intolerance after renal transplantation: impact of immunosuppressive and antihypertensive drug therapy", Clin J Am Soc Nephrol, 1, pp.575~582 (2006)
- Bee YM, "Incidence and risk factors for development of new-onset diabetes after kidney transplantation", Ann Acad Med Singapore, 40, pp.160~167 (2011)
- Cosio FG, "Patient survival after renal transplantation:IV. Impact of post-transplant diabetes", Kidney Int, 62, pp.1440~1446 (2002)
- Luan FL, "New-onset diabetes mellitus in kidney transplant recipients discharged on steroid-free immunosuppression", Transplantation, 91, pp.334~341 (2011)
- Rodrigo E, "New-onset diabetes after kidney transplantation: risk factors", J Am Soc Nephrol, 17(12 Suppl 3), pp.S291~S295 (2006)
- Montori VM, "Posttransplantation diabetes: a systematic review of the literature", Diabetes Care, 25, pp.583~592 (2002)
- Israni AK, "OPTN", SRTR 2012 annual data report : deceased organ donation, 2014, pp.14(Suppl 1), 167~183
- Larson TS, "Complete avoidance of calcineurin inhibitors in renal transplantation: a randomized trial comparing sirolimus and tacrolimus", Am J Transplant, 6, pp.514~522 (2006)
- Wullschleger S, "Molecular organization of target of rapamycin complex 2", J Biol Chem, 280, pp.30697~30704 (2005)
- Johnston O, "Sirolimus is associated with new-onset diabetes in kidney transplant recipients", J Am Soc Nephrol, 19, pp.1411~1418 (2008)
- Yang SB, "Rapamycin ameliorates age-dependent obesity associated with increased mTOR signaling in hypothalamic POMC neurons", Neuron, 75, pp.425~436 (2012)
- Ratner RE, "Long-term effects of exenatide therapy over 82 weeks on glycaemic control and weight in over-weight metformin-treated patients with type 2 diabetes mellitus", Diabetes Obes Metab, 8, pp.419~428 (2006)
- Sharif A, "Complications associated with new-onset diabetes after kidney transplantation", Nat Rev Nephrol, 8, pp.34~42 (2012)
- Kurian B, "Effectiveness and longterm safety of thiazolidinediones and metformin in renal transplant recipients", Endocr Pract, 14, pp.979~984 (2008)
- Hwang H, "Comparison of adverse drug reaction profiles of two tacrolimus formulations in rats", Immunopharmacol Immunotoxicol, 34, pp.434~442 (2012)
- Song HK, "Influence of sirolimus on cyclosporine-induced pancreas islet dysfunction in rats", Am J Transplant, 9, pp.2024~2033 (2009)
- Cheng JT, "Novel mechanism for plasma glucose-lowering action of metformin in streptozotocin-induced diabetic rats", Diabetes, 55, pp.819~825 (2006)
- Shivaswamy V, "Metformin improves immunosuppressant induced hyperglycemia and exocrine apoptosis in rats", Transplantation, 95, pp.280~284 (2013)
- Choi YH, "Dose-independent pharmacokinetics of metformin in rats: hepatic and gastrointestinal first-pass effects", J Pharm Sci, 95, pp.2543~2552 (2006)
- Quaile MP, "Toxicity and toxicokinetics of metformin in rats", Toxicol Appl Pharmacol, 243, pp.340~347 (2010)
- Jin L, "Dipeptidyl peptidase IV inhibitor MK-0626 attenuates pancreatic islet injury in tacrolimus-induced diabetic rats", PLoS One, 9, pp.e100798~ (2014)
- Lim SW, "Inhibition of dipeptidyl peptidase IV protects tacrolimus-induced kidney injury", Lab Invest, 95, pp.1174~1185 (2015)
- Piao SG, "Drug interaction between cyclosporine and mTOR inhibitors in experimental model of chronic cyclosporine nephrotoxicity and pancreatic islet dysfunction", Transplantation, 93, pp.383~389 (2012)
- Shivaswamy V, "Tacrolimus and sirolimus have distinct effects on insulin signaling in male and female rats", Transl Res, 163, pp.221~231 (2014)
- Pernicova I, "Metformin: mode of action and clinical implications for diabetes and cancer", Nat Rev Endocrinol, 10, pp.143~156 (2014)
- Akkan AG, "Insulinotropic action of AICA riboside. I. Insulin release by isolated islets and the perfused pancreas", Diabetes Res, 25, pp.13~23 (1994)
- Leclerc I, "Role of AMP-activated protein kinase in the regulation of gene transcription", Biochem Soc Trans, 30, pp.307~311 (2002)
- Saeedi R, "Metabolic actions of metformin in the heart can occur by AMPK-independent mechanisms", Am J Physiol Heart Circ Physiol, 294, pp.H2497~H2506 (2008)
- 임선우, "Role of dipeptidyl peptidase-4 inhibitors in new-onset diabetes after transplantation", The Korean Journal of Internal Medicine, 30(6), pp.759~770 (2015), 대한내과학회[DOI]
- Jeong YK, "Metformin radiosensitizes p53-deficient colorectal cancer cells through induction of G2", M arrest and inhibition of DNA repair proteins, 2015, pp.10, e0143596~
- Jang EK, "Metformin is associated with a favorable outcome in diabetic patients with cervical lymph node metastasis of differentiated thyroid cancer", Eur Thyroid J, 4, pp.181~188 (2015)